



	Soul Healthcare (India) Pvt. Ltd 7 th KM Jaspur Road Kashipur-244713 (U.K) (An ISO 9001:2015 and GMP Certified Company)		
	CERTIFICATE OF ANALYSIS (Under Drugs & Cosmetics Act, 1940 & Rules Made There Under)		

Name of Sample	ONDE-LEAP-4 MD Tablets (Ondansetron Orally Disintegrating Tablets IP 4 mg)	A.R. Number	SHPT/470/26
Batch No.	T-261043	Reference No.	SFPT/470/26
Batch Size	1,20,000 tablets	Date of Receiving	19/10/2026
Date of Mfg.	Oct. 2026	Date of Completion	20/10/2026
Date of Exp.	Sep. 2028	Sample of Quantity	50 Tabs.
Manufactured By	Soul Healthcare (I) Pvt. Ltd	Mfg. Lic. No.	43/UA/2007
Manufactured for	AIOCD PHARMA LIMITED	Ref. to Protocols	In House Specification

Name of Test		Specification	Result of Analysis	
Description		Yellow colored round, biconvex, uncoated orally disintegrating tablets.	Complies	
Identification		Positive for Ondansetron Hydrochloride	Complies	
Average weight		NLT 148.4 mg to NMT 172.5 mg	160.5 mg	
Uniformity of weight		NMT two of the individual weight deviates from the average weight by more than the ± 7.5 percent and none deviate by more than the ± 15 percent.	Minimum – 1.86% Maximum +2.24%	
Disintegration time		Not more than 30 Second	12 Second	
Dissolution		NLT 85 % of the stated amount of $C_{18}H_{19}N_3O$.	102.72 %	
Friability		Not more than 1 % w/w	0.32 % w/w	
Uniformity of Contents		The tablet comply the individual values obtained is the limit 85 % to 115 % of the average contents	With in limit	
Uniformity of Dispersion		All the particles should pass through 22 sieves No.	Complies	
Related substances		Complies	Complies	
Assay	Each uncoated orally disintegrating tablet on an average weight contains			
Name of Ingredient		Claim	Observed	Limit
Ondansetron HCl IP Eq. to Ondansetron		4 mg	4.05 mg	NLT 3.6 mg to NMT 4.4 mg

Opinion : In the opinion of the undersigned, the sample referred to above is STANDARD QUALITY with respect to above specification.			
Sign. & Date	Prepared By	Checked By	Approved By
	 20/10/2026	 20/10/2026	 20/10/2026